Choroideremia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Choroideremia Market Outlook

Thelansis’s “Choroideremia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Choroideremia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Choroideremia Overview

Choroideremia is a rare X-linked recessive genetic disorder characterized by progressive vision loss, primarily affecting males. It is caused by mutations in the CHM gene located at Xq21.2, responsible for producing the Rab escort protein-1 (REP-1). In affected males, the condition typically manifests as night blindness (nyctalopia) during their first or second decade. This is followed by a narrowing of the peripheral visual field, with a progression from ring-shaped blind spots (annular scotomas) to a more extensive visual field loss. Visual acuity impairment becomes noticeable by mid-adulthood. Over time, changes in the fundus (the back of the eye) are observed, initially showing pigmentary stippling and focal areas of choroid atrophy in the equatorial fundus. In the advanced stages, extensive degenerative changes occur in the retinal pigment epithelium (RPE), with only remnants of the choroidal blood vessels remaining apparent in the macula, far peripheral retina, and near the optic disc. At this stage, the sclera becomes visible during fundus examination in areas where the choroidal and RPE atrophy is complete. Managing Choroideremia involves regular ophthalmologic examinations to monitor the condition's progression or the emergence of cataracts. Additionally, individuals are advised to use UV-blocking sunglasses to protect their eyes. Unfortunately, there is currently no available treatment for Choroideremia.

• Choroideremia is considered a rare disorder, with an estimated prevalence of 1 in 50,000 to 100,000 people.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: